13035-19-3

Usage

Uses

Used in Pharmaceutical Industry:
4-Aminopiperidine is used as a reactant for the synthesis of various pharmaceutical compounds, including:
1. Cdk5/p25 kinase inhibitors for the treatment of neurodegenerative diseases.
2. Antimalarials to combat malaria, a life-threatening disease caused by parasites.
3. Selective cyclin-dependent kinase 4/6 inhibitors, which have potential applications in cancer therapy.
4. IKKβ inhibitors, which can be used to modulate the immune response and treat inflammatory conditions.
5. Orally bioavailable P2Y12 antagonists for the inhibition of platelet aggregation, useful in the prevention and treatment of cardiovascular diseases.
6. Human and murine soluble epoxide hydrolase inhibitors, which may have implications in the treatment of hypertension and other related conditions.
These applications highlight the importance of 4-Aminopiperidine as a versatile and valuable compound in the development of new drugs and therapies across different medical fields.

InChI:InChI=1/C5H12N2/c6-5-1-3-7-4-2-5/h5,7H,1-4,6H2

Upstream product

• 504-24-5 4-aminopyridine 
• 856846-18-9 N-(1-acetyl-[4]piperidyl)-acetamide 
• 626-61-9 4-Chloropyridine 
• 14906-56-0 4-Acetamino-pyridin-1-oxid 
• 1124-33-0 4-nitraminopyridine N-oxide 
• 64-17-5 ethanol 
• 7664-93-9 sulfuric acid 
• 178667-08-8 [4]piperidyl-dicarbothioamidoic acid 
• 7553-56-2 iodine 
• 7732-18-5 water 
• 50541-93-0 4-amino-1-benzylpiperidine 
• 100368-03-4 piperidine-4-carboxylic acid hydrazide; dihydrochloride 

Downstream Products

• 1016820-77-1 N-sec-butyl-4-aminopiperidine 
• 614753-18-3 4-{1-[4-(4-amino-piperidin-1-ylmethyl)-benzyl]-5,6-dichloro-1H-benzoimidazol-2-yl}-piperidine-1-carboxylic acid tert-butyl ester 
• 614753-11-6 4-{5,6-dichloro-1-[4-(piperidin-4-ylaminomethyl)-benzyl]-1H-benzoimidazol-2-yl}-piperidine-1-carboxylic acid tert-butyl ester 
• 63921-23-3 1-phenylpiperidin-4-ylamine 
• 23056-29-3 phenyl-piperidin-4-yl-amine 
• 260360-16-5 4-N-(2-methoxyphenyl)aminopiperidine 
• 1029643-92-2 N-phenylmethylidenepiperidinyl-4-amine 
• 501673-75-2 1-tert-butoxycarbonyl-4-[(2-methoxyphenyl)amino]piperidine 
• 933056-02-1 1-tert-butoxycarbonyl-4-[(2-ethylphenyl)amino]piperidine 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 529509-52-2 N-(1-{4-[1-(3-fluoro-benzyl)-1H-indazol-5-ylamino]-pyrrolo[2,1-f][1,2,4]triazin-5-ylmethyl}-piperidin-4-yl)-formamide 

Related news

4-Aminopiperidine (cas 13035-19-3) derivatives as a new class of potent cognition enhancing drugs09/09/2019

Extrusion of one of the nitrogens of the piperazine ring of potent nootropic drugs previously described gave 4-aminopiperidine analogues that maintained high cognition enhancing activity in the mouse passive avoidance test. One of the new compounds (9, active at 0.01 mg/kg ip) may represent a ne...detailed

Design and synthesis of novel small molecule CCR2 antagonists: Evaluation of 4-Aminopiperidine (cas 13035-19-3) derivatives09/08/2019

A novel N-(2-oxo-2-(piperidin-4-ylamino)ethyl)-3-(trifluoromethyl)benzamide series of human CCR2 chemokine receptor antagonists was identified. With a pharmacophore model based on known CCR2 antagonists a new core scaffold was designed, analogues of it synthesized and structure–affinity relatio...detailed

Evaluation of a 4-Aminopiperidine (cas 13035-19-3) replacement in several series of CCR5 antagonists09/04/2019

The bicyclic 5-amino-3-azabicyclo[3.3.0]octanes were shown to be effective replacements for the conformationally restricted 4-aminopiperidine ring found in several series of CCR5 antagonists.detailed

Relevant academic research and scientific papers

USE OF INTERMEDIATES ((R ) -2,2, 4-TRIMETHYL-L, 3-DIOXOLANE-4-YL) METHANOL (A), 3-F LUORO-4-NITRO-PHENOL (B) AND 1- (4-CHLORO- BENZYL) -PIPERIDIN-4-YLAMINE (C)

The present invention relates to novel processes for the preparation of intermediate compounds which can be used to prepare therapeutic agents. The present invention also relates to novel intermediate compounds which can be used to prepare therapeutic agents. More specifically, the invention relates to the use of intermediates ((R) -2,2,4-trimethyl-l, 3- dioxolane-4 -yl) methanol (A), 3-f luoro-4-nitro-phenol (B) and 1- (4-chloro-benZyl) -piperidin-4-ylamine (C).

The effect of substitution on the utility of piperidines and octahydroindoles for reversible hydrogen storage

Substituted piperidines and octahydroindoles are compared in terms of their usability as reversible organic hydrogen storage liquids for hydrogen-powered fuel cells. Theoretical Gaussian calculations indicate which structural features are likely to lower the enthalpy of dehydrogenation. Experimental results show that attaching electron donating or conjugated substituents to the piperidine ring greatly increases the rate of catalytic dehydrogenation, with the greatest rates being observed with 4-aminopiperidine and piperidine-4-carboxamide. Undesired side reactions were observed with some compounds such as alkyl transfer reactions during the dehydrogenation of 4-dimethylaminopiperidine, C-O and C-N cleavage reactions during hydrogenation and/or subsequent dehydrogenation of 4-alkoxy and 4-amino indoles, and disproportionation during the hydrogenation of 4-aminopyridine. The Royal Society of Chemistry and the Centre National de la Recherche Scientifique.

Indazole derivatives having monocyclic amine

An indazole compound having the formula (I): wherein: R1 is hydrogen, C1 -C6 alkyl, C3 -C6 alkenyl or C3 -C6 cycloalkyl; Q is carbonyl, thiocarbonyl or methylene; and R2 is a group of the formula (II) or (IV); STR1 wherein R1 is C1 -C6 alkyl, C3 -C6 alkenyl or benzyl, of which a phenyl group thereof is optionally mono- or di-substituted by the same or different halogen or methoxy; m is 0 to 2; n and o is 1 or 2. The compound exhibits 5-HT4 receptor agonist activity.

Molecular features associated with polyamine modulation of NMDA receptors

The effect of 1,3-diamines on basal and spermine-stimulated [3H]MK-801 binding was investigated. Systematic variations in the molecular parameters revealed that, in general, lipophilic 1,3-diamines inhibited and hydrophilic 1,3-diamines enhance